For more than a decade, one question has hung over adjuvant bisphosphonates in early breast cancer: which patients actually benefit? Today the answer rests largely on menopausal status. Inbiomotion argues that tumor biology can do better, and US oncologists can now order its test. On November 18, the Barcelona company announced that its MAF Test® is available across the United States through NeoGenomics Laboratories.
At a glance
- What: a FISH-based tissue test that detects MAF gene amplification in the primary breast tumor
- Where: United States, through NeoGenomics Laboratories
- Who can order: oncologists and pathologists
- Addressable population: about 258,000 newly diagnosed early-stage breast cancer patients a year in the US, according to Inbiomotion
- Evidence base: retrospective biomarker analyses of the AZURE and NSABP B-34 trials
U.S. availability marks a major step in making precision medicine a reality

Joël Jean-Mairet, PhD/www.juliusbaer.com
said Joël Jean-Mairet, PhD, Executive Chairperson of Inbiomotion. He said the company aims to improve outcomes and reduce unnecessary treatment. Ordering information is available from NeoGenomics.
The problem with menopause as a filter
Guidelines back adjuvant bisphosphonates for postmenopausal patients. The ASCO–Ontario Health (Cancer Care Ontario) guideline says they should be discussed with all postmenopausal patients who are candidates for adjuvant systemic therapy, whether menopause is natural or treatment-induced. ESMO recommends them for postmenopausal women at intermediate to high risk of recurrence. This approach reflects trial data in which the recurrence and survival benefits appeared confined to postmenopausal women, for reasons that have remained unclear.
Inbiomotion argues that tumor biology, not menopausal status, should drive the decision. When the MAF gene at 16q23 is amplified, tumors overproduce MAF, a transcription factor tied to metastasis, particularly to bone.
The implication cuts both ways. The company says MAF-negative patients may be eligible for bisphosphonates, including patients who are not postmenopausal and are not covered by current guidelines. It also says MAF-positive patients, including some postmenopausal women, may get no benefit or may be harmed. Inbiomotion reports that about 80% of patients in the trial specimens were MAF-negative.
For US practice, one more point matters. Bisphosphonates do not have regulatory approval for adjuvant use in early breast cancer, so their use in this setting rests on guideline recommendations. Inbiomotion has said in earlier announcements that, for this reason, the MAF Test is not authorized as a companion diagnostic.
What the trials showed
The data come from archived tumor samples from two large adjuvant trials. Both trials were designed to test the drugs, not the biomarker.
- AZURE (zoledronic acid), The Lancet Oncology, 2017.
- The trial enrolled 3,360 patients with stage II–III disease.
- Of 1,739 patients with tumor samples, 865 had assessable MAF results, and 21% of those tumors were MAF-positive.
- In MAF-negative tumors, zoledronic acid was associated with better invasive disease-free survival (HR 0.74; 95% CI 0.56–0.98).
- The signal that drew attention came from MAF-positive patients who were not postmenopausal. Among these 121 women, zoledronic acid was associated with worse invasive disease-free survival (HR 2.47) and overall survival (HR 2.27).
- NSABP B-34 (oral clodronate vs placebo), JNCI Cancer Spectrum, 2021.
- The double-blind trial randomized 3,323 women with stage I–III disease at 162 centers in the US and Canada.
- Its MAF analysis was set up to validate the AZURE findings. Of 2,533 available tumor samples, 1,883 were evaluable.
- At five years, MAF non-amplified patients on clodronate had better disease-free survival (HR 0.70; 95% CI 0.51–0.94) and overall survival (HR 0.59; 95% CI 0.37–0.93).
- In MAF-amplified tumors, clodronate showed no benefit, with possible harm in some subgroups.
Both were retrospective analyses, and in both the MAF testing was done blind at a central laboratory. Inbiomotion helped fund both analyses. Company founders and executives, including Roger Gomis and Jean-Mairet, are co-authors.
Guideline traction and debate
In January 2026, Inbiomotion announced that the MAF Test had been included in the 2025 update of Spain’s SEOM-GEICAM-SOLTI clinical guidelines for early-stage breast cancer. The guideline cites better invasive disease-free, disease-free and overall survival with adjuvant bisphosphonates in MAF-negative tumors. It lists the test as an option for identifying patients likely to benefit and those who should avoid the drugs. It grades that statement III, B, compared with I, A for its core bisphosphonate recommendation.
Not everyone is convinced. In October 2025, Health Technology Wales concluded that the evidence was insufficient to support routine adoption of MAF testing. It noted that the data come from retrospective subgroup analyses of trials that did not test MAF-guided treatment prospectively. Its economic modeling suggested the test could be cost-effective, but the same uncertainties apply to that model. It called for prospective and real-world studies.
What to watch
The US is the largest market yet for a test Inbiomotion launched in May 2023. Distribution partners already cover:
- Spain and Portugal (Palex Medical)
- Italy (SPA Farma)
- the UK and Ireland (Source BioScience)
- Sub-Saharan Africa (The Scientific Group)
- South Korea (HJ HyupJin), since May 2026
Three questions will shape what happens next:
- Coverage: whether US payers reimburse the test
- Guidelines: whether US panels such as NCCN and ASCO take a position on MAF testing
- Practice: whether MAF results begin to change who receives adjuvant bisphosphonates in US clinics
The announcement did not include specimen requirements, turnaround time, price or the test’s US regulatory status.
About the companies
Inbiomotion is a spin-off of IRB Barcelona and ICREA, founded in 2011 by Prof. Roger Gomis after the MAF gene was identified as a biomarker of bone metastasis in breast cancer. The company holds more than 200 patents and patent applications covering the MAF Test and the use of bisphosphonates in early-stage breast cancer. Its main investors are Ysios Capital, Caixa Capital Risc, Alta Life Sciences and the Vila Casas Foundation.
NeoGenomics, Inc. (NASDAQ: NEO) is a provider of oncology diagnostic solutions that enable precision medicine. It is headquartered in Fort Myers, Florida, and runs a network of CAP-accredited, CLIA-certified laboratories across the US.
Read more on insights on OncoDaily Biotech.